

2026 ISV Pre-Congress Satellite Workshop - From Outbreak to Readiness

11 October 2026 – A Room with a Zoo, Antwerp, Belgium – Room: Gorilla 1

Special Workshop 1: 11:00-13:00

Organized by *EVA Therapeutics, USA*

AI HI 4 LMIC

Artificial Intelligence Informed by Human Intelligence for Low-and Middle-Income Countries

11:00-11:10	Welcome ➤ EVA Therapeutics Mission and Vision Jeffrey T. Safrit , <i>CEO, EVA Therapeutics, USA</i>
11:10-11:25	How LMIC Vaccine Developers can access Computational Vaccinology Tools at EVA Therapeutics ➤ AI/Hi Tools for Vaccine Design used by EVA Tx ➤ Current Equitable Vaccine Access Projects at EVA Tx Annie De Groot , <i>EVA Therapeutics, USA</i>
11:25-11:40	Case study 1: VennVax Mpox Vaccine Progress ➤ Development of an mRNA Mpox vaccine in Cape Town, South Africa Hapiloe Maranyane-Tshililo , <i>Afrigen Biologics, South Africa</i>
11:40-11:55	Case study 2: Universal Influenza Vaccine “UTIV” ➤ Development of a cross-conserved, universal T cell epitope-driven vaccine for influenza Dan Hoft , <i>Saint Louis University, USA</i>
11:55-12:00	Questions / Closing Remarks Jeffrey T. Safrit , <i>CEO, EVA Therapeutics, USA</i>

12:00–13:00 LUNCH (SPONSORED BY EVA THERAPEUTICS)

Special Workshop 2: 13:00-18:00

Co-Organized by *The National Research Council Canada (NRC), Canada* and *The International Vaccine Institute (IVI), South Korea*

Vaccine Manufacturing & Global Preparedness in the Context of the Current Ebola BDBV Outbreak

13:00-13:50	Session I: Current Status of Outbreak Session Chair: Manon Cox , <i>NextWaveBio / ISV President, USA</i>
13:00–13:10	Welcome, Opening Remarks and Workshop Objectives Manon Cox , <i>NextWaveBio / ISV President, USA</i> Lakshmi Krishnan , <i>Vice President, Life Sciences, NRC, Canada / ISV Board Member</i> In-Kyu Yoon , <i>Deputy Director General, Integrated Development and Pandemic Readiness, IVI, South Korea</i>
13:10–13:30	Keynote Speaker: Ebola Bundibugyo Outbreak — Current Status Yazdan Yazdanpanah , <i>Director, ANRS Emerging Infectious Diseases, France</i>
13:30–13:50	Responding to Bundibugyo: 100 Days into the Ebola Epidemic, CEPI's Perspective Katrin Ramsauer , <i>Program Lead/Deputy technical lead Bundibugyo response, CEPI, Austria</i>
14:00-14:40	Session II: Current Outbreak on the Ground Response Session Chair: Margaret Liu , <i>ProTherImmune / ISV Board Member, USA</i>
14:00–14:20	African R&D and Manufacturing Readiness Nicaise Ndembe , <i>Deputy Director General, IVI Africa Regional Office, Rwanda</i>
14:20–14:40	DRC Ground Response Wessam Mankoula , <i>African CDC Regional Director for Northern Africa at the RCC, Acting Head of Emergency Preparedness and Response, Egypt</i>
14:45-15:30	Session III: Bio-Medical Countermeasures Preparedness Session Chair: Lakshmi Krishnan , <i>Vice President, Life Sciences, NRC, Canada / ISV Board Member</i>
14:45–15:00	Canada's Biomedical Countermeasures Initiative – BDBV responsiveness Rhonda KuoLee , <i>Executive Director, Biomedical Countermeasures Challenge Program, National Research Council Canada (NRC), Canada</i>
15:00–15:15	rVSV-EBOV Vaccination Protects Ferrets from Lethal Bundibugyo Virus Disease Logan Banadyga , <i>Scientist, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada</i> <i>Secondary Affiliation: Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada</i>
15:15–15:30	From Bundibugyo to Disease X: Readiness for the Next Outbreak In-Kyu Yoon , <i>Deputy Director General, Integrated Development and Pandemic Readiness, IVI, South Korea</i>
15:30–15:40	COFFEE BREAK
15:40-16:40	Session IV: BDBV Vaccine Approaches Session Chair: In-Kyu Yoon , <i>Deputy Director General, Integrated Development and Pandemic Readiness, IVI, South Korea</i>
15:40–16:00	From Cross-Reactivity to Protection: Opportunities and Challenges in BDBV Vaccine Development Wim Adriaensen , <i>Associate Professor Clinical Immunology Unit, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium</i>
16:00–16:20	Preclinical Development and Phase 1 Evaluation of Moderna's mRNA-1469 for Bundibugyo Ebolavirus Hamilton Bennett , <i>Executive Director, Resilience and R&D and Partnerships Moderna, USA</i>

16:20–16:40	ChAdOx Platform: Crisis to Preparedness, Vaccine Development During and Between Outbreaks Teresa Lambe , <i>Vaccines and Immunology, University of Oxford, United Kingdom</i>
16:45–17:45	Session V: Vaccine Manufacturing & Regional Efforts Session Chair: Amine Kamen , <i>McGill University, Canada</i>
16:45–17:00	Adapting rVSV Vaccine Manufacturing for Rapid Outbreak Responses Ali Allouche , <i>Vice President, Business Development & Alliance Management, Hillemann Laboratories, Singapore</i>
17:00–17:15	Bharat Biotech — Manufacturing and Vaccine Responsiveness Badri Narayan Patnaik , <i>Director of Clinical Development, Bharat Biotech, India</i>
17:15–17:30	CanSino Biologics: Ad5-EBOV to Ad5-BDBV: Platform Conversion and Biomanufacturing Readiness for Filovirus Outbreak Preparedness Chunlin Xin , <i>Vice President, External R&D and Scientific Affairs, CanSino Biologics Inc., China</i>
17:30–17:45	Stranded Capacity, Live Outbreak: What Bundibugyo Tells Africa About Vaccine Manufacturing Readiness Michael Lusiola , <i>Director, Regionalized Vaccine Manufacturing Collaborative, Africa</i>
17:45–18:00	Closing Remarks Lakshmi Krishnan , <i>Vice President, Life Sciences, NRC, Canada / ISV Board Member</i> In-Kyu Yoon , <i>Deputy Director General, Integrated Development and Pandemic Readiness, IVI, South Korea</i>